APOE4 was originally studied in the context of blood lipids and cardiovascular disease and first characterized at the protein level as one of three inherited ApoE isoforms with unique ...
Nicotinamide riboside (NR) is a patented analog of nicotinamide or Vitamin B3, and is sold as a dietary supplement under the brand name Tru Niagen. Cells use NR to synthesize NAD+, an essential ...
Perlman Neurology Outpatient Clinic 8950 Villa La Jolla Drive Suite C129 La Jolla, CA92037 United States Visit Website Contact: Douglas Galasko, M.D Phone: 858-657-8540 E-mail: [email protected] ...
The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...
Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...
Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...
The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...
In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...
Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback